46 related articles for article (PubMed ID: 25929297)
1. Serum fibroblast growth factor 21 in overweight and obese Thai children and adolescents: its relation to glucose metabolism and its change after glucose loading.
Korwutthikulrangsri M; Mahachoklertwattana P; Chanprasertyothin S; Pongratanakul S; Poomthavorn P
Clin Endocrinol (Oxf); 2015 Dec; 83(6):820-7. PubMed ID: 25929297
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 21, adiposity, and macronutrient balance in a healthy, pregnant population with overweight and obesity.
Sutton EF; Morrison CD; Stephens JM; Redman LM
Endocr Res; 2018 Nov; 43(4):275-283. PubMed ID: 29768065
[TBL] [Abstract][Full Text] [Related]
3. FGF21 Is Associated with Acanthosis Nigricans in Obese Patients.
Huang Y; Yang J; Li Y; Chen J; Song K; Wang X; Bu L; Cheng X; Wang J; Qu S
Int J Endocrinol; 2016; 2016():1658062. PubMed ID: 27190511
[TBL] [Abstract][Full Text] [Related]
4. Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients.
Bagheri L; Hami M; Mojahedi MJ; Ghorban Sabbagh M; Ayatollahi H
J Renal Inj Prev; 2016; 5(2):79-84. PubMed ID: 27471739
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.
Véniant MM; Sivits G; Helmering J; Komorowski R; Lee J; Fan W; Moyer C; Lloyd DJ
Cell Metab; 2015 May; 21(5):731-8. PubMed ID: 25955208
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
Dong JQ; Rossulek M; Somayaji VR; Baltrukonis D; Liang Y; Hudson K; Hernandez-Illas M; Calle RA
Br J Clin Pharmacol; 2015 Nov; 80(5):1051-63. PubMed ID: 25940675
[TBL] [Abstract][Full Text] [Related]
7. Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1.
Samms RJ; Smith DP; Cheng CC; Antonellis PP; Perfield JW; Kharitonenkov A; Gimeno RE; Adams AC
Cell Rep; 2015 May; 11(7):991-9. PubMed ID: 25956583
[TBL] [Abstract][Full Text] [Related]
8. Latest approaches for the treatment of obesity.
Jackson VM; Breen DM; Fortin JP; Liou A; Kuzmiski JB; Loomis AK; Rives ML; Shah B; Carpino PA
Expert Opin Drug Discov; 2015; 10(8):825-39. PubMed ID: 25967138
[TBL] [Abstract][Full Text] [Related]
9. Adipokines in health and disease.
Fasshauer M; Blüher M
Trends Pharmacol Sci; 2015 Jul; 36(7):461-70. PubMed ID: 26022934
[TBL] [Abstract][Full Text] [Related]
10. Serum FGF21 levels are associated with brown adipose tissue activity in humans.
Hanssen MJ; Broeders E; Samms RJ; Vosselman MJ; van der Lans AA; Cheng CC; Adams AC; van Marken Lichtenbelt WD; Schrauwen P
Sci Rep; 2015 May; 5():10275. PubMed ID: 25985218
[TBL] [Abstract][Full Text] [Related]
11. Association between Serum Fibroblast Growth Factor 21 and Coronary Artery Disease in Patients with Type 2 Diabetes.
Kim WJ; Kim SS; Lee HC; Song SH; Bae MJ; Yi YS; Jeon YK; Kim BH; Kim YK; Kim IJ
J Korean Med Sci; 2015 May; 30(5):586-90. PubMed ID: 25931789
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor 21 and Fetuin-A in Obese Adolescents With and Without Type 2 Diabetes.
Reinehr T; Karges B; Meissner T; Wiegand S; Fritsch M; Holl RW; Woelfle J
J Clin Endocrinol Metab; 2015 Aug; 100(8):3004-10. PubMed ID: 26052728
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals.
Hanks LJ; Gutiérrez OM; Bamman MM; Ashraf A; McCormick KL; Casazza K
J Clin Transl Endocrinol; 2015 Jun; 2(2):77-82. PubMed ID: 26042208
[TBL] [Abstract][Full Text] [Related]
14. Non-pharmacological and pharmacological strategies of brown adipose tissue recruitment in humans.
Lee P; Greenfield JR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 2():184-90. PubMed ID: 26026310
[TBL] [Abstract][Full Text] [Related]
15. Brown Adipose Tissue and Browning Agents: Irisin and FGF21 in the Development of Obesity in Children and Adolescents.
Pyrżak B; Demkow U; Kucharska AM
Adv Exp Med Biol; 2015; 866():25-34. PubMed ID: 26022904
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice.
Xu P; Zhang Y; Wang W; Yuan Q; Liu Z; Rasoul LM; Wu Q; Liu M; Ye X; Li D; Ren G
Dig Dis Sci; 2015 Oct; 60(10):3032-43. PubMed ID: 26003555
[TBL] [Abstract][Full Text] [Related]
17. Fat and carbohydrate in western diet contribute differently to hepatic lipid accumulation.
Wu W; Tsuchida H; Kato T; Niwa H; Horikawa Y; Takeda J; Iizuka K
Biochem Biophys Res Commun; 2015 Jun; 461(4):681-6. PubMed ID: 25931000
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between the Serum FGF21 Level and Growth in Children of Short Stature.
Lee YJ; Jung SY; Lee YA; Kim J; Lee SY; Shin CH
J Korean Med Sci; 2023 Feb; 38(7):e63. PubMed ID: 36808549
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Metabolically Healthy and Metabolically Unhealthy Obese Children.
Akduman F; Şıklar Z; Özsu E; Doğan Ö; Kır MK; Berberoğlu M
J Clin Res Pediatr Endocrinol; 2022 Dec; 14(4):433-443. PubMed ID: 35859690
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 21, Adiponectin, and Irisin as Markers of Unfavorable Metabolic Features in 12-Year-Old Children.
Seppä S; Tenhola S; Voutilainen R
J Endocr Soc; 2019 Apr; 3(4):825-837. PubMed ID: 30963140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
